| |
|
|
|
|
|
|
|||
|
Blood, 1 January 2005, Vol. 105, No. 1, pp. 3-4.
Clotting hits the wallUNIVERSITY OF ILLINOIS AT URBANA-CHAMPAIGN
Recent studies have suggested that blood-borne tissue factor (in leukocyte-derived microparticles) plays an essential role in thrombus growth. This study uses bone marrow transplantation of genetically modified mice to show that macrovascular thrombosis is driven by tissue factor in the vessel wall, not leukocyte-derived tissue factor.
In this issue of Blood, Day and colleagues cleverly use genetically modified mice to evaluate the relative contributions of leukocyte-derived and vessel wall tissue factor to macrovascular thrombosis. Tissue factornull mice die as early embryos, precluding their use in such experiments. Instead, Day et al employed mice genetically modified to express only 1% of the normal level of tissue factor. These low-tissue-factor mice are highly resistant to the development of both arterial and venous thrombosis (following photochemical injury of the carotid artery or ligation of the inferior vena cava). But the reduction in thrombosis could be due either to lower expression of tissue factor in the vessel wall, or to lower levels of blood-borne tissue factor. To address this question, they used bone marrow transplantation between wild-type and low-tissue-factor mice to create animals which were deficient only in leukocyte-derived tissue factor, or alternatively, which had wild-type leukocytes but low tissue factor throughout the rest of their bodies. Significantly, the low-tissue-factor mice that had wild-type leukocytes were fully protected against arterial and venous thrombosis, whereas the wild-type mice with low-tissue-factor leukocytes were not. These results suggest that macrovascular thrombosis is dependent solely on the level of tissue factor present in the vessel wall and not at all on the expression of blood-borne tissue factor derived from leukocytes. Interestingly, another study recently published in Blood 5 (from some of the same authors of the present study) used the same bone marrow transplantation strategy with the same type of mice to examine this question in a mouse model of microvascular thrombosis (using laser-induced arterial injury). In contrast to the findings of Day et al, they found that leukocyte-derived tissue factor contributed significantly to thrombus propagation. There are many differences between these 2 studies in terms of the site and manner of injury, the size of the arteries under study, whether or not occlusive thrombi were studied, and the technologies used to study thrombus formation, which could explain the differences in conclusions. It is tempting to speculate that the relative contributions of blood-borne and vessel wall tissue factor to thrombosis may depend on how much tissue-factor activity is initially exposed following vascular injury. This innovative mouse model will be enormously useful in examining these questions in detail. References
Related Article in Blood Online:
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Copyright © 2005 by American Society of Hematology Online ISSN: 1528-0020 | |||||||||